Tenet Healthcare (THC) delivered a large headline beat. Adjusted EPS of $6.64 topped the $4.60 consensus by 31.5% and cleared the $5.05 Earnings Whisper number. Adjusted EPS grew 79.5% year over year. Revenue of $5.631 billion beat the $5.47 billion consensus by 2.9% and grew 6.5%, faster than the 5.3% pace for the first nine months. Management also raised full-year adjusted EBITDA guidance for a second straight quarter. The quality of the beat deserves scrutiny, however. A meaningful share of the upside came from one-time Conifer transition items and out-of-period Medicaid money, while several core growth metrics kept decelerating. That is the central tension.

The GAAP figure is not the right yardstick. Diluted EPS of $12.41, versus $3.86 a year ago, was inflated by $646 million of contract-termination revenue tied to the early end of Conifer's revenue-cycle agreement with CommonSpirit. The adjusted numbers exclude that item, but they are not entirely clean either. The earlier-than-planned transition triggered a $97 million cumulative catch-up in net operating revenue. Tenet explicitly called this timing-related, pulled forward from later in the year. Transition efficiencies added roughly $50 million more, producing a $147 million net benefit to adjusted EBITDA. The Hospital segment also booked $32 million of prior-year Medicaid supplemental revenue. Reported consolidated EBITDA margin was 24.1%. Excluding these items, the call analysis puts core margin near 21.8%, below the 23.2% reported in the second quarter.

Beneath the headline, the operating picture is mixed rather than weak.

The hospital business is getting more patients but less revenue per patient:

• Same-hospital adjusted admissions accelerated for a third straight quarter: +0.6%, +2.6%, then +3.2%.
• ER visits rose 4.0%.
• Core hospital EBITDA grew about 11% excluding transition items.
• Revenue per adjusted admission, however, slowed sharply to +0.2% from +3.3% in Q2.
• Exchange revenue fell 18%, worse than the 17% and 9% declines in the prior two quarters, and uncompensated care ticked up.

USPI, the ambulatory franchise investors treat as the crown jewel, held margins but kept losing growth:

• Adjusted EBITDA rose 9.1% to $537 million.
• Margin reached 39.2%.
• Total joint replacements reaccelerated to 12.8% growth.
• Same-facility revenue growth has stepped down every quarter, from 7.2% to 5.3% to 5.0% to 4.5%.
• Cases fell 1.5%, and management described the surgical environment as "not gangbusters."

The guidance raise reads better than it is. Adjusted EBITDA is now expected at $5.05 billion to $5.20 billion, up $195 million at the midpoint, after a $295 million lift in Q2. Adjusted free cash flow guidance rose $100 million. Management itself called the Q3 raise "pretty mechanical," and the core outlook was essentially unchanged from Q2. Conifer transition activities are now expected to contribute about $450 million of one-time 2026 EBITDA. For 2027, management offered only the framing of enterprise EBITDA growth excluding those items, leaving a tough comparison for the reported figure.

Bears have legitimate ammunition on policy as well:

• Medicaid work requirements loom, with roughly 60% of admissions coming from expansion states.
• Exchange headwinds are still being sized for 2027.
• An undisclosed share of about $356 million in quarterly supplemental Medicaid payments is exposed to H.R.1 reductions.

The balance sheet and cash story is the cleaner part of the report. Q3 adjusted free cash flow was $1.1 billion, and $2.5 billion year to date. Leverage fell to 2.11x from 2.33x. A $2 billion 2034 note issue refinanced the 2027 and part of the 2028 maturities, leaving no significant maturities until 2028. USPI put more than $100 million into Q3 acquisitions and is tracking toward a raised target above $300 million. Buybacks, however, slowed to $255 million from $1.04 billion in Q2.

Investors entered the report cautious but less so than before. Earnings Whispers sentiment improved from -0.16 to -0.07, which is still slightly negative. The stock has been treated far better than that sentiment implies. Shares closed at $268.50 ahead of the release, up 14.3% from the open after the July report and 22.4% above the 200-day moving average. They sat about 5% below the $283.05 52-week high set in late August. The Earnings Whispers trend readings are mostly positive, with price, momentum and AVWAP all favorable while sequential growth is neutral. With the stock near the upper end of its range, much of the good news on cash and leverage appears already reflected, while the deceleration and policy questions are not.

The bottom line is that Tenet's quarter was genuinely strong on cash generation, deleveraging and hospital volumes, but the size of the beat and the guidance raise overstate the core momentum. Strip out the $147 million Conifer benefit and the out-of-period Medicaid, and investors are left with slowing USPI revenue growth, flat hospital pricing, deepening exchange losses and a $450 million non-recurring hurdle for 2027. With the stock trading well above its long-term average, the next debate is less about 2026 and more about how much underlying growth remains once the one-time items roll off.